FGFR2-related Syndromic Craniosynostosis Program

About Krouzon Pharmaceuticals

Krouzon Pharmaceuticals is a private, preclinical biotech targeting a significant unmet need in pediatric rare diseases, specifically FGFR2-related craniosynostosis syndromes like Crouzon, Pfeiffer, and Apert syndromes. The company's foundation is built on the founder's 25+ years of specialized research, including the creation of the world's first disease models for these conditions and the discovery of novel therapeutic targets. With a lean team and experienced advisors, Krouzon aims to develop a non-surgical therapeutic alternative to the current standard of care, which involves multiple, lifelong, high-risk surgeries for affected children.

Therapeutic Areas